Month: October 2025
Excerpt from the Press Release: Neuraptive Therapeutics, Inc., a biotechnology company focused on developing novel therapies to improve outcomes in peripheral nerve injuries (PNI), today announced the first patient has been enrolled in its phase 3 clinical trial using NTX-001 in peripheral nerve injuries due to trauma. The phase 3 study is a multicenter, randomized,…
Read More
Cemsidomide in Combination With Dexamethasone Achieved a 50% Overall Response Rate (ORR) at the Highest Dose Level (100 µg) and a 40% ORR at the 75 µg Dose Level in a Heavily Pre-Treated Relapsed/Refractory Multiple Myeloma Patient Population Responses Across Dose Levels With Median Duration of Response of 9.3 Months as of the Data Cut-off…
Read More
Results from OVATION 2 Study reinforce IMNN-001 efficacy benefits observed in the clinic and unique mechanism of action, producing key anti-cancer immune cytokines post-treatment Pivotal Phase 3 trial of IMNN-001 underway, with four trial sites activated to date and on plan for site expansion to accelerate patient recruitment Excerpt from the Press Release: LAWRENCEVILLE, N.J.,…
Read More
Excerpt from the Press Release: ZUG, Switzerland and BOSTON and SAN DIEGO and SHANGHAI, Sept. 22, 2025 (GLOBE NEWSWIRE) — CRISPR Therapeutics (NASDAQ: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, and Sirius Therapeutics, a clinical stage biotech company developing innovative small interfering RNA (siRNA) therapies for global markets, today announced that the first patient has been…
Read More- « Previous
- 1
- 2
- 3